Simon Stertzer Acquires 70,200 Shares of BioCardia (NASDAQ:BCDA) Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer purchased 70,200 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $0.92 per share, with a total value of $64,584.00. Following the completion of the acquisition, the director owned 127,338 shares in the company, valued at approximately $117,150.96. This trade represents a 122.86% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

BioCardia Stock Performance

BioCardia stock opened at $1.09 on Friday. The stock has a market cap of $12.40 million, a P/E ratio of -1.20 and a beta of 0.51. BioCardia, Inc. has a fifty-two week low of $0.78 and a fifty-two week high of $2.45. The firm’s fifty day moving average price is $1.01 and its 200-day moving average price is $1.17.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.04). Sell-side analysts predict that BioCardia, Inc. will post -0.76 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of BioCardia in a report on Tuesday, June 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $25.00.

Institutional Investors Weigh In On BioCardia

Several hedge funds have recently added to or reduced their stakes in the company. Cetera Investment Advisers purchased a new position in shares of BioCardia in the 2nd quarter worth about $40,000. Geode Capital Management LLC raised its holdings in shares of BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after buying an additional 27,263 shares in the last quarter. Finally, DRW Securities LLC purchased a new position in shares of BioCardia during the 4th quarter valued at about $72,000. Institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.